JP2002145783A - Encapsulated pharmaceutical preparation containing s-adenosylmethionine or its salts - Google Patents
Encapsulated pharmaceutical preparation containing s-adenosylmethionine or its saltsInfo
- Publication number
- JP2002145783A JP2002145783A JP2000338007A JP2000338007A JP2002145783A JP 2002145783 A JP2002145783 A JP 2002145783A JP 2000338007 A JP2000338007 A JP 2000338007A JP 2000338007 A JP2000338007 A JP 2000338007A JP 2002145783 A JP2002145783 A JP 2002145783A
- Authority
- JP
- Japan
- Prior art keywords
- adenosylmethionine
- oil
- capsule
- weight
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、Ｓ−アデノシルメ
チオニンまたはその塩類を含有するカプセル製剤に関す
る。The present invention relates to a capsule preparation containing S-adenosylmethionine or a salt thereof.
【０００２】[0002]
【従来の技術】Ｓ−アデノシルメチオニンは、鬱病の改
善や関節炎の緩和に有効であるとされており、また、中
国等では肝硬変等の肝臓病患者にも処方されている。し
かし、Ｓ−アデノシルメチオニンは、非常に吸湿し易い
特性を持っており、従来は錠剤にしか製造できなかっ
た。しかも、この錠剤は硬度が高く、保管は容易である
が、崩壊性が悪く、崩壊試験機で測定した錠剤の破壊時
間は１時間以上となった。そこで、米国人等は錠剤を噛
んで食べるものもあるが、この錠剤は、噛んで割るのも
困難な程、固いものとなっているため、Ｓ−アデノシル
メチオニンは優れた薬効を有しながら、あまり実用化さ
れていなかった。また、Ｓ−アデノシルメチオニンの味
は、酸味が非常に強いため、日本人にとって、味わって
食べることは困難であり、水と一緒に飲むことができる
カプセル製剤とされることが求められる。2. Description of the Related Art S-adenosylmethionine is said to be effective in improving depression and alleviating arthritis. In China and other countries, S-adenosylmethionine is prescribed for patients with liver diseases such as cirrhosis. However, S-adenosylmethionine has the property of being very easily absorbed by moisture, and conventionally could only be manufactured into tablets. Moreover, the tablet had high hardness and was easy to store, but had poor disintegration, and the tablet breaking time measured by a disintegration tester was 1 hour or more. Therefore, some Americans chew and eat tablets, but since these tablets are so hard that they are difficult to chew and break, S-adenosylmethionine has excellent medicinal properties. , Was not very practical. In addition, since the taste of S-adenosylmethionine is very sour, it is difficult for Japanese to taste and eat it, and it is required to prepare a capsule preparation that can be taken with water.
【０００３】[0003]
【発明が解決しようとする課題】本発明は、かかるＳ−
アデノシルメチオニンを、誰もが飲みやすく、容易に薬
効が期待できるカプセル製剤として提供することを課題
とする。SUMMARY OF THE INVENTION The present invention relates to such S-
An object of the present invention is to provide adenosyl methionine as a capsule preparation that is easy for anyone to drink and that can easily be expected to have a medicinal effect.
【０００４】[0004]
【課題を解決するための手段】我々は、Ｓ−アデノシル
メチオニンまたはその塩類を素早く食用油に乳化・分散
させることにより、大気中の水分を吸湿させることなく
油溶中に封じ込め安定化させることを見い出し、本発明
を完成した。Means for Solving the Problems We aim to stabilize the S-adenosylmethionine or its salts by rapidly emulsifying and dispersing it in edible oil without containing moisture in the atmosphere while absorbing the oil. And completed the present invention.
【０００５】即ち、本発明のカプセル製剤は、Ｓ−アデ
ノシルメチオニンまたはその塩類を、油液中に分散又は
懸濁した液体を、ゼラチンを主成分とするカプセル外皮
に封入したものである。That is, the capsule preparation of the present invention is obtained by dispersing or suspending S-adenosylmethionine or a salt thereof in an oil solution in a capsule shell mainly composed of gelatin.
【０００６】Ｓ−アデノシルメチオニンは、塩類として
使用されてもよいが、この塩類は有機酸又は無機酸のい
ずれの酸との塩でもよく、例えば硫酸、燐酸、塩酸、ｐ
−トルエンスルホン酸等のベンゼンスルホン酸誘導体、
メタンスルホン酸やエタンスルホン酸等のアルキルスル
ホン酸、ブタンジスルホン酸等のアルキルジスルホン
酸、コンドロイチン硫酸等との塩類が使用できる。Ｓ−
アデノシルメチオニンまたはその塩類は単独で使用され
ても２種以上併用されてもよい。[0006] S-adenosylmethionine may be used as salts, which may be salts with either organic or inorganic acids, for example, sulfuric acid, phosphoric acid, hydrochloric acid, p-acid.
-Benzenesulfonic acid derivatives such as toluenesulfonic acid,
Salts with alkylsulfonic acids such as methanesulfonic acid and ethanesulfonic acid, alkyldisulfonic acids such as butanedisulfonic acid, and chondroitin sulfate can be used. S-
Adenosylmethionine or salts thereof may be used alone or in combination of two or more.
【０００７】次に、本発明において油液とは、食用油を
主成分とする液体のことで、油液中には油分と共に乳化
剤と増粘剤を含ませるのがよい。乳化剤と増粘剤の添加
により、Ｓ−アデノシルメチオニン等と油分が分離する
ことなく、均一なエマルジョンの製造が可能となる。Next, in the present invention, the oil liquid is a liquid containing edible oil as a main component, and the oil liquid preferably contains an emulsifier and a thickener together with an oil component. By adding the emulsifier and the thickener, it is possible to produce a uniform emulsion without separating oil from S-adenosylmethionine and the like.
【０００８】本発明で使用する食用油としては、サンフ
ラワー油、シソ油、月見草油、ゴマ油、ヤシ油、小麦胚
芽油、玄米胚芽油、オリーブ油、コーン油、米サラダ
油、大豆油、ハト麦油、マカデミア油等の植物油、及び
魚油、卵油、卵黄油等の動物油が例示でき、乳化剤とし
ては、グリセリン脂肪酸エステル、レシチン、ショ糖脂
肪酸エステル、プロピレングリコール脂肪酸エステル、
ソルビタン脂肪酸エステル、動植物ステロール等が例示
でき、増粘剤としては、ミツロウ、植物ワックス、硬化
油等が例示できる。[0008] Edible oils used in the present invention include sunflower oil, perilla oil, evening primrose oil, sesame oil, coconut oil, wheat germ oil, brown rice germ oil, olive oil, corn oil, rice salad oil, soybean oil, pigeon oil Vegetable oils such as macadamia oil, and animal oils such as fish oil, egg oil and egg yolk oil. Examples of the emulsifier include glycerin fatty acid ester, lecithin, sucrose fatty acid ester, propylene glycol fatty acid ester,
Examples of the sorbitan fatty acid ester, animal and plant sterols, and the like, and examples of the thickener include beeswax, vegetable wax, and hardened oil.
【０００９】油の使用量は、カプセル外皮に封入される
液体の３０〜９０重量％程度でよく、４０〜８０重量％
程度であるのが好ましく、特に５５〜６５重量％程度で
あるのがよい。また、乳化剤と増粘剤の合計使用量は、
１〜６０重量％程度でよく、２〜２０重量％程度である
のが好ましく、特に４〜１０重量％程度であるのがよ
い。The amount of the oil used may be about 30 to 90% by weight of the liquid sealed in the capsule shell, and may be 40 to 80% by weight.
It is preferably about 55 to 65% by weight. Also, the total amount of emulsifier and thickener used is
It may be about 1 to 60% by weight, preferably about 2 to 20% by weight, and particularly preferably about 4 to 10% by weight.
【００１０】なお、Ｓ−アデノシルメチオニン又はその
塩類は、カプセル外皮に封入される液体中に１〜５０重
量％の範囲で含ませることができる。[0010] S-adenosylmethionine or a salt thereof can be contained in a range of 1 to 50% by weight in the liquid sealed in the capsule shell.
【００１１】Ｓ−アデノシルメチオニン又はその塩類は
非常に吸湿性が高い粉末であり、空気中に放置して置く
と空気中の水分を吸収し、数時間で糊状となってしま
い、成分が分解をしてしまうので、本発明では、ベース
となる油に乳化剤や増粘剤を予め溶解した後、Ｓ−アデ
ノシルメチオニン又はその塩類（粉末）を開封し素早く
計量して、油の中に封じ込め外気の影響を受けないよう
にするのがよい。S-adenosylmethionine or a salt thereof is a powder having a very high hygroscopicity. If left in the air, it absorbs the moisture in the air and becomes a paste in a few hours. In the present invention, the emulsifier or thickener is dissolved in advance in the base oil, and then S-adenosylmethionine or a salt thereof (powder) is opened and quickly weighed, so that the oil is decomposed. It is better not to be affected by the outside air.
【００１２】分散は、ミキサーで空気が入らないように
短時間で実施する。大量生産する場合には、真空条件下
（例えば７００〜７６０ｍｍＨｇ) で分散するのがよ
い。なお、この作業は、通常、湿度が４０％以下の空調
設備が整った室内で行うのが好ましい。The dispersion is carried out in a short time so that no air enters the mixer. In the case of mass production, it is preferable to disperse under vacuum conditions (for example, 700 to 760 mmHg). In addition, it is preferable that this work is usually performed in a room equipped with air conditioning equipment having a humidity of 40% or less.
【００１３】なお、本発明におけるカプセル外皮はゼラ
チを主成分とするのであればよく、軟カプセルであって
も、硬カプセルであってもよい。カプセル外皮は、ゼラ
チン１００重量部に対して可塑剤を０〜１００重量部程
度添加混合したものからなるものであってもよい。The outer shell of the capsule in the present invention is only required to contain gelatin as a main component, and may be a soft capsule or a hard capsule. The capsule shell may be formed by mixing and adding about 0 to 100 parts by weight of a plasticizer to 100 parts by weight of gelatin.
【００１４】カプセルの製法には、公知の方法、例えば
浸漬法、打ち抜き法又は滴下法等がいずれも適用でき
る。Any known method, such as a dipping method, a punching method or a dropping method, can be applied to the method for producing the capsule.
【００１５】[0015]
【発明の実施の形態】次に、本発明の実施例及び安定性
試験の結果を示す。 実施例１ (1) サフラワー油（植物油）６０％、グリセリン脂肪酸
エステル（乳化剤）2.５％、ミツロウ（増粘剤）2.５％
を加熱溶解した後、２０℃まで冷却したエマルジョンに
Ｓ−アデノシルメチオニンパラトルエンスルホン酸 ２
硫酸塩原料（ＳＡＭｅ）を３５％加え、混合攪拌し、減
圧脱泡を行い懸濁液を製造する。 (2) 懸濁液のＳ−アデノシルメチオニン含量の定量を行
い、１００％含有していることを確認する。 (3) ゼラチン１００重量部、グリセリン３５重量部、カ
ラメル色素４重量部、精製水８０重量部を６５〜７０℃
で加温溶解した後、減圧脱泡し、外皮溶液を製造する。 (4) ロータリーダイ式軟カプセル成型充填機に、(3) の
外皮溶液と(1) 懸濁液を供給し、カプセル成型（金型サ
イズ：ＯＢＬＯＮＧ ＮＯ．１１）を行った後、２５℃
±２℃の除湿エアーで、４８時間乾燥する。 (5) 乾燥後のカプセル内容物に含まれるＳ−アデノシル
メチオニン含量の定量を行う。 (6) 安定性試験において１ヶ月２ヶ月３ヶ月後のＳ−ア
デノシルメチオニン含量の定量を行う。 (7) 軟カプセル中のＳ−アデノシルメチオニン含量は、
カプセル成型時で３％分解したが、その後、分解が停止
し、３ヶ月経過後も９７％の含有を確認した。 (8) 日本薬局方の崩壊試験法による崩壊性試験では、３
ヶ月経過後でも２０分以内で崩壊した。なお、比較のた
めに、Ｓ−アデノシルメチオニン含有薬剤として市販の
Jarrow社製錠剤（Ｓ−アデノシルメチオニン含量：表示
２００mg、測定値２０１〜２０８mg）について、前記同
様の崩壊性試験を実施したところ、１時間経過後でも崩
壊されなかった。次に、実施例１の製品の常温保管での
経時変化の試験結果を、次表に示す（定量試験は、液体
クロマトグラフィーで実施した）。Next, examples of the present invention and the results of stability tests will be described. Example 1 (1) Safflower oil (vegetable oil) 60%, glycerin fatty acid ester (emulsifier) 2.5%, beeswax (thickener) 2.5%
Was heated and dissolved, and then cooled to 20 ° C. to give S-adenosylmethionine paratoluenesulfonic acid 2
35% of a sulfate raw material (SAMe) is added, mixed and stirred, and defoamed under reduced pressure to produce a suspension. (2) The S-adenosylmethionine content of the suspension is quantified, and it is confirmed that the suspension contains 100%. (3) 100 parts by weight of gelatin, 35 parts by weight of glycerin, 4 parts by weight of caramel dye, and 80 parts by weight of purified water were heated at 65 to 70 ° C.
After heating and dissolving in, defoaming is performed under reduced pressure to produce an outer skin solution. (4) The capsule solution (mold size: OBLONG No. 11) is supplied to the rotary die-type soft capsule molding and filling machine by supplying the shell solution of (3) and the suspension (1), and then at 25 ° C.
Dry with dehumidified air at ± 2 ° C for 48 hours. (5) The content of S-adenosylmethionine contained in the dried capsule contents is determined. (6) In the stability test, the S-adenosylmethionine content is determined after one month, two months and three months. (7) The content of S-adenosylmethionine in the soft capsule is:
Decomposition was 3% at the time of capsule molding, but after that, decomposition was stopped, and it was confirmed that 97% was contained even after 3 months. (8) In the disintegration test by the disintegration test method of the Japanese Pharmacopoeia, 3
Disintegrated within 20 minutes even after a lapse of months. For comparison, a commercially available S-adenosylmethionine-containing drug was used.
When a disintegration test similar to the above was carried out on a tablet manufactured by Jarrow (S-adenosylmethionine content: indicated 200 mg, measured value 201 to 208 mg), it was not disintegrated even after 1 hour. Next, the test results of the change over time of the product of Example 1 during storage at room temperature are shown in the following table (the quantitative test was performed by liquid chromatography).
【００１６】[0016]
【表１】 [Table 1]
【００１７】実施例２ (1) サフラワー油（植物油）６８％、グリセリン脂肪酸
エステル（乳化剤）3.５％、ミツロウ（増粘剤）3.５％
を加熱溶解した後、２０℃まで冷却したエマルジョンに
Ｓ−アデノシルメチオニンパラトルエンスルホン酸 ２
硫酸塩原料（ＳＡＭｅ）を２５％加え、混合攪拌し、減
圧脱泡を行い懸濁液を製造する。 (2) 懸濁液のＳ−アデノシルメチオニン含量の定量を行
い、１００％含有していることを確認する。 (3) ゼラチン１００重量部、グリセリン３５重量部、カ
ラメル色素７重量部、精製水８０重量部を６５〜７０℃
で加温溶解した後、減圧脱泡し、外皮溶液を製造する。 (4) ロータリーダイ式軟カプセル成型充填機に、(3) の
外皮溶液と(1) 懸濁液を供給し、カプセル成型（金型サ
イズ：ＯＶＡＬ ＮＯ．7.５）を行った後、２５℃±２
℃の除湿エアーで、４８時間乾燥する。 (5) 乾燥後のカプセル内容物に含まれるＳ−アデノシル
メチオニン含量の定量を行う。 (6) 安定性試験において１ヶ月２ヶ月３ヶ月後のＳ−ア
デノシルメチオニン含量の定量を行う。 (7) 軟カプセル中のＳ−アデノシルメチオニン含量は、
カプセル成型時で３％分解したが、その後、分解が停止
し、３ヶ月経過後も９７％の含有を確認した。 (8) 実施例１と同様の崩壊性試験では、３ヶ月経過後で
も２０分以内で崩壊した。 次に実施例２の常温保管での製品の経時変化の試験結果
を、次表に示す。Example 2 (1) 68% safflower oil (vegetable oil), 3.5% glycerin fatty acid ester (emulsifier), 3.5% beeswax (thickener)
Was heated and dissolved, and then cooled to 20 ° C. to give S-adenosylmethionine paratoluenesulfonic acid 2
25% of a sulfate raw material (SAMe) is added, mixed and stirred, and defoamed under reduced pressure to produce a suspension. (2) The S-adenosylmethionine content of the suspension is quantified, and it is confirmed that the suspension contains 100%. (3) 100 parts by weight of gelatin, 35 parts by weight of glycerin, 7 parts by weight of caramel pigment, and 80 parts by weight of purified water were heated at 65 to 70 ° C.
After heating and dissolving in, defoaming is performed under reduced pressure to produce an outer skin solution. (4) The outer solution of (3) and the suspension (1) are supplied to a rotary die-type soft capsule molding and filling machine, and capsule molding (mold size: OVAL No. 7.5) is performed. ° C ± 2
Dry for 48 hours with dehumidified air at ℃. (5) The content of S-adenosylmethionine contained in the dried capsule contents is determined. (6) In the stability test, the S-adenosylmethionine content is determined after one month, two months and three months. (7) The content of S-adenosylmethionine in the soft capsule is:
Decomposition was 3% at the time of capsule molding, but after that, decomposition was stopped, and it was confirmed that 97% was contained even after 3 months. (8) In the disintegration test similar to that in Example 1, the disintegration occurred within 20 minutes even after 3 months. Next, the test results of the change over time of the product in the room temperature storage in Example 2 are shown in the following table.
【００１８】[0018]
【表２】 [Table 2]
【００１９】なお、Ｓ−アデノシルメチオニンは、３０
℃前後から分解が始まり、温度が上昇するにつれて、加
速度的に分解が進むことがわかった。Ｓ−アデノシルメ
チオニン原料を３０℃及び４０℃に２ヶ月間保管し、そ
の間のＳ−アデノシルメチオニンの分解率を測定した結
果を、次表に示す。It should be noted that S-adenosylmethionine is 30
It was found that decomposition started at around ℃, and the decomposition accelerated as the temperature increased. The S-adenosylmethionine raw material was stored at 30 ° C. and 40 ° C. for 2 months, and the results of measuring the decomposition rate of S-adenosylmethionine during that time are shown in the following table.
【００２０】[0020]
【表３】 [Table 3]
【００２１】このように、Ｓ−アデノシルメチオニンは
耐熱性に劣るため、カプセル内容物の調製は、２５℃以
下で実施するのが好ましく、また、製品カプセル製剤の
保管温度は２０℃以下とするのがよい。As described above, since S-adenosylmethionine is inferior in heat resistance, the preparation of the capsule contents is preferably carried out at 25 ° C. or lower, and the storage temperature of the product capsule preparation is 20 ° C. or lower. Is good.
【００２２】[0022]
【発明の効果】本発明では、Ｓ−アデノシルメチオニン
またはその塩類を崩壊性に優れたカプセル製剤として提
供できるため、Ｓ−アデノシルメチオニンまたはその塩
類を食品や医薬品として、幅広く利用可能とする。According to the present invention, S-adenosylmethionine or salts thereof can be provided as a capsule preparation having excellent disintegration properties, so that S-adenosylmethionine or salts thereof can be widely used as foods and pharmaceuticals.
【手続補正書】[Procedure amendment]
【提出日】平成１２年１２月８日（２０００．１２．
８）[Submission date] December 8, 2000 (200.12.
8)
【手続補正１】[Procedure amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００４[Correction target item name] 0004
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【０００４】[0004]
【課題を解決するための手段】我々は、Ｓ−アデノシル
メチオニンまたはその塩類を素早く食用油に乳化・分散
させることにより、大気中の水分を吸湿させることなく
油液中に封じ込め安定化させることを見い出し、本発明
を完成した。SUMMARY OF THE INVENTION We have found that by rapidly emulsifying and dispersing S-adenosylmethionine or a salt thereof in an edible oil, it is possible to stabilize the S-adenosylmethionine by containing it in an oil solution without absorbing moisture in the atmosphere. And completed the present invention.
【手続補正２】[Procedure amendment 2]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００８[Correction target item name] 0008
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【０００８】本発明で使用する食用油としては、サフラ
ワー油、シソ油、月見草油、ゴマ油、ヤシ油、小麦胚芽
油、玄米胚芽油、オリーブ油、コーン油、米サラダ油、
大豆油、ハト麦油、マカデミア油等の植物油、及び魚
油、卵油、卵黄油等の動物油が例示でき、乳化剤として
は、グリセリン脂肪酸エステル、レシチン、ショ糖脂肪
酸エステル、プロピレングリコール脂肪酸エステル、ソ
ルビタン脂肪酸エステル、動植物ステロール等が例示で
き、増粘剤としては、ミツロウ、植物ワックス、硬化油
等が例示できる。The edible oils used in the present invention include safflower oil, perilla oil, evening primrose oil, sesame oil, coconut oil, wheat germ oil, brown rice germ oil, olive oil, corn oil, rice salad oil,
Soybean oil, oat oil, vegetable oils such as macadamia oil, and animal oils such as fish oil, egg oil, and yolk oil can be exemplified. Examples of emulsifiers include glycerin fatty acid ester, lecithin, sucrose fatty acid ester, propylene glycol fatty acid ester, and sorbitan fatty acid. Examples of the thickener include beeswax, vegetable waxes, and hardened oils.
【手続補正３】[Procedure amendment 3]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】００１３[Correction target item name] 0013
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【００１３】なお、本発明におけるカプセル外皮はゼラ
チンを主成分とするのであればよく、軟カプセルであっ
ても、硬カプセルであってもよい。カプセル外皮は、ゼ
ラチン１００重量部に対して可塑剤を０〜１００重量部
程度添加混合したものからなるものであってもよい。The outer shell of the capsule in the present invention is only required to contain gelatin as a main component, and may be a soft capsule or a hard capsule. The capsule shell may be formed by mixing and adding about 0 to 100 parts by weight of a plasticizer to 100 parts by weight of gelatin.
【手続補正４】[Procedure amendment 4]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】００１６[Correction target item name] 0016
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【００１６】[0016]
【表１】 [Table 1]
【手続補正５】[Procedure amendment 5]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】００１８[Correction target item name] 0018
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【００１８】[0018]
【表２】 [Table 2]
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｐ 25/24 Ａ６１Ｐ 25/24 (72)発明者 内田 陽介 東京都中央区日本橋室町４丁目１番21号 株式会社興人内 (72)発明者 美矢 豊文 東京都中央区日本橋室町４丁目１番21号 株式会社興人内 (72)発明者 佐藤 宏次 東京都中央区日本橋室町４丁目１番21号 株式会社興人内 (72)発明者 横山 淳 東京都千代田区丸ノ内３丁目４番１号 ミ ヤコ化学株式会社内 (72)発明者 深澤 武仁 山梨県南巨摩郡南部町南部7764番地 アリ メント工業株式会社内 (72)発明者 杉井 喜久 山梨県南巨摩郡南部町南部7764番地 アリ メント工業株式会社内 Ｆターム(参考） 4C076 AA53 AA55 AA58 BB01 CC01 CC04 CC16 DD38 DD46 EE42 EE53 EE57 FF68 4C086 AA01 EA18 MA03 MA05 MA37 MA52 NA10 ZA12 ZA75 ZA96──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61P 25/24 A61P 25/24 (72) Inventor Yosuke Uchida 4-1-21, Nihonbashi Muromachi, Chuo-ku, Tokyo Kojinnai Co., Ltd. (72) Inventor Toyofumi Miya 4-1-1, Nihonbashi Muromachi, Chuo-ku, Tokyo Kojinnai Co., Ltd. (72) Koji Sato, 4-1-1 Nihonbashi Muromachi, Chuo-ku, Tokyo Kojinnai Co., Ltd. (72) Inventor Atsushi Yokoyama 3-4-1, Marunouchi, Chiyoda-ku, Tokyo Miyako Chemical Co., Ltd. (72) Inventor Takehito Fukasawa 7774 South Nambu-cho, Minamikoma-gun, Yamanashi Ariment Industry Co., Ltd. (72) Inventor Yoshihisa Sugii 7764, Nanbu-cho, Minamikoma-gun, Yamanashi Prefecture Ariment Industries Co., Ltd. F-term (reference) 4C076 AA53 AA55 AA58 BB01 CC01 CC04 CC16 DD38 DD46 EE42 EE53 EE57 FF68 4C086 AA01 EA18 MA03 MA05 MA37 MA52 NA10 ZA12 ZA75 ZA96
Claims (6)
類を、油液中に分散又は懸濁した液体を、ゼラチンを主
成分とするカプセル外皮に封入したカプセル製剤。1. A capsule preparation in which a liquid in which S-adenosylmethionine or a salt thereof is dispersed or suspended in an oil solution is enclosed in a capsule shell containing gelatin as a main component.
ものである請求項１のカプセル製剤。2. The capsule preparation according to claim 1, wherein the oil solution contains an emulsifier and a thickener in the oil.
類が、前記液体中に１〜５０重量％の範囲で含まれる請
求項１又は２のカプセル製剤。3. The capsule preparation according to claim 1, wherein S-adenosylmethionine or a salt thereof is contained in the liquid in an amount of 1 to 50% by weight.
は滴下法により製造された請求項１〜３いずれか１項の
カプセル製剤。4. The capsule preparation according to claim 1, wherein the capsule is produced by a dipping method, a punching method, or a dropping method.
量部に対して可塑剤を０〜１００重量部添加してなるも
のである請求項１〜４いずれか１項のカプセル製剤。5. The capsule preparation according to any one of claims 1 to 4, wherein the capsule shell is obtained by adding 0 to 100 parts by weight of a plasticizer to 100 parts by weight of gelatin.
類が、前記油液中に、真空条件下で分散又は懸濁されて
いる請求項１〜５いずれか１項のカプセル製剤。6. The capsule preparation according to claim 1, wherein S-adenosylmethionine or a salt thereof is dispersed or suspended in the oil solution under vacuum conditions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000338007A JP2002145783A (en) | 2000-11-06 | 2000-11-06 | Encapsulated pharmaceutical preparation containing s-adenosylmethionine or its salts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000338007A JP2002145783A (en) | 2000-11-06 | 2000-11-06 | Encapsulated pharmaceutical preparation containing s-adenosylmethionine or its salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002145783A true JP2002145783A (en) | 2002-05-22 |
Family
ID=18813296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000338007A Pending JP2002145783A (en) | 2000-11-06 | 2000-11-06 | Encapsulated pharmaceutical preparation containing s-adenosylmethionine or its salts |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002145783A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010235616A (en) * | 2005-06-30 | 2010-10-21 | Luca Maria De | Salt or complex of methyl donor with phytic acid or its derivative, and method for synthesis thereof |
| US10231934B2 (en) | 2009-09-24 | 2019-03-19 | Capsugel Belgium Nv | Acid resistant capsules |
-
2000
- 2000-11-06 JP JP2000338007A patent/JP2002145783A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010235616A (en) * | 2005-06-30 | 2010-10-21 | Luca Maria De | Salt or complex of methyl donor with phytic acid or its derivative, and method for synthesis thereof |
| US10231934B2 (en) | 2009-09-24 | 2019-03-19 | Capsugel Belgium Nv | Acid resistant capsules |
| US10874619B2 (en) | 2009-09-24 | 2020-12-29 | Capsugel Belgium, NV | Acid resistant capsules |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2395286C2 (en) | Pharmaceutical compositions containing conjugated estrogens and bazedoxifene | |
| NO138683B (en) | BASIC FOR USE IN THE PREPARATION OF A PHARMACEUTICAL PREPARATION WITH SLOW RELEASE OF THE ACTIVE INGREDIENT | |
| EA006550B1 (en) | Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof | |
| NO327294B1 (en) | Composition for forming an enteric coating on an oral composition, the composition provided with an enteric coating and method for preparing such a preparation. | |
| JPS5948415A (en) | Long time active matrix tablet | |
| EP0161915B1 (en) | Etoposide soft capsules | |
| JPS641442B2 (en) | ||
| BR112019021391A2 (en) | pullulan capsules | |
| BRPI0417339B1 (en) | Soft butylphthalide capsule | |
| JP2005137935A (en) | Hard capsule and its production method | |
| JP2005021124A (en) | Film preparation for oral cavity | |
| JPS62294618A (en) | Use of glycofurol for liquefying medicine filled in soft gelatin capsule | |
| JP2002145783A (en) | Encapsulated pharmaceutical preparation containing s-adenosylmethionine or its salts | |
| CN100475216C (en) | Compound lycopene formulation for women and preparation process thererof | |
| CN106511294B (en) | A kind of soft capsule and preparation method thereof | |
| KR20060035779A (en) | Masticatable capsule and process for producing the same | |
| JP3278427B2 (en) | Method for producing capsules | |
| JP6929939B2 (en) | Stabilization of beta-hydroxyisovaleric acid preparation in softgel capsules | |
| JP6267066B2 (en) | Controlled release soft capsule | |
| JP6926453B2 (en) | Capsule composition | |
| JP7360103B2 (en) | Soft capsules containing hydroxytyrosol | |
| JP2012051945A (en) | Capsule, method for manufacturing the same, and capsule wall | |
| GB2090138A (en) | Suppositories containing trimethoprim/sulphamethoxazole and a phospholipid | |
| JP2021172663A (en) | Gelatin agent containing lubiprostone and method for producing the same | |
| JP2023041452A (en) | Gelatin agent and method for producing the same, and method for inhibiting moisture absorption of gelatin agent |